Suppr超能文献

两个纵向队列中β淀粉样蛋白生物标志物的变化及其与APOE基因分型的关联

Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.

作者信息

Resnick Susan M, Bilgel Murat, Moghekar Abhay, An Yang, Cai Qing, Wang Mei-Cheng, Thambisetty Madhav, Prince Jerry L, Zhou Yun, Soldan Anja, Wong Dean F, O'Brien Richard J, Ferrucci Luigi, Albert Marilyn S

机构信息

Laboratory of Behavioral Neuroscience, Intramural Research Program, National Institute on Aging, Baltimore, MD, USA.

Laboratory of Behavioral Neuroscience, Intramural Research Program, National Institute on Aging, Baltimore, MD, USA; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.

出版信息

Neurobiol Aging. 2015 Aug;36(8):2333-9. doi: 10.1016/j.neurobiolaging.2015.04.001. Epub 2015 Apr 4.

Abstract

Apolipoprotein E (APOE) genotype influences onset age of Alzheimer's disease but effects on disease progression are less clear. We investigated amyloid-β (Aβ) levels and change in relationship to APOE genotype, using 2 different measures of Aβ in 2 different longitudinal cohorts. Aβ accumulation was measured using positron emission tomography (PET) imaging and (11)C-Pittsburgh compound-B (PiB) in 113 Baltimore Longitudinal Study of Aging participants (mean age 77.3 years; 107 normal, 6 cognitively impaired) and cerebral spinal fluid (CSF) Aβ1-42 assays in 207 BIOCARD study participants (mean age 62 years; 195 normal, 12 cognitively impaired). Participants in both cohorts had up to 7 serial assessments (mean 2.3-2.4). PET-PiB retention increased and CSF Aβ1-42 declined longitudinally. APOE ε4 was significantly associated with higher PET-PiB retention and lower CSF Aβ1-42, independent of age and sex, but APOE genotype did not significantly affect Aβ change over time. APOE ε4 carriers may be further along in the disease process, consistent with earlier brain Aβ deposition and providing a biological basis for APOE genotype effects on onset age of Alzheimer's disease.

摘要

载脂蛋白E(APOE)基因型影响阿尔茨海默病的发病年龄,但对疾病进展的影响尚不清楚。我们在两个不同的纵向队列中使用两种不同的β淀粉样蛋白(Aβ)测量方法,研究了Aβ水平及其与APOE基因型的关系变化。在113名巴尔的摩纵向衰老研究参与者(平均年龄77.3岁;107名正常,6名认知受损)中,使用正电子发射断层扫描(PET)成像和(11)C-匹兹堡化合物-B(PiB)测量Aβ积累;在207名BIOCARD研究参与者(平均年龄62岁;195名正常,12名认知受损)中,检测脑脊液(CSF)Aβ1-42。两个队列的参与者均进行了多达7次的系列评估(平均2.3 - 2.4次)。PET-PiB滞留量纵向增加,CSF Aβ1-42纵向下降。独立于年龄和性别,APOE ε4与较高的PET-PiB滞留量和较低的CSF Aβ1-42显著相关,但APOE基因型并未显著影响Aβ随时间的变化。APOE ε4携带者在疾病进程中可能进展得更远,这与早期脑Aβ沉积一致,并为APOE基因型对阿尔茨海默病发病年龄的影响提供了生物学基础。

相似文献

1
Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.
Neurobiol Aging. 2015 Aug;36(8):2333-9. doi: 10.1016/j.neurobiolaging.2015.04.001. Epub 2015 Apr 4.
2
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status.
Alzheimers Dement. 2014 Jan;10(1):e9-e18. doi: 10.1016/j.jalz.2013.01.007. Epub 2013 Mar 26.
3
Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.
4
Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories.
Neurobiol Aging. 2020 Oct;94:111-120. doi: 10.1016/j.neurobiolaging.2020.05.012. Epub 2020 May 31.
5
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.
6
APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.
J Alzheimers Dis. 2019;69(3):783-793. doi: 10.3233/JAD-181282.
7
High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.
Alzheimers Dement. 2014 Sep;10(5):530-540.e1. doi: 10.1016/j.jalz.2013.03.010. Epub 2013 Aug 24.
8
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.
Ann Neurol. 2010 Jan;67(1):122-31. doi: 10.1002/ana.21843.
9
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study.
Dement Geriatr Cogn Disord. 2010;29(3):204-12. doi: 10.1159/000281832. Epub 2010 Mar 20.
10
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.
Arch Neurol. 2012 May;69(5):636-43. doi: 10.1001/archneurol.2011.845.

引用本文的文献

1
Alzheimer's disease cerebrospinal fluid biomarker levels and APOE genetic status are associated with hippocampal-cerebellar functional connectivity.
Neurobiol Aging. 2025 Jul;151:107-116. doi: 10.1016/j.neurobiolaging.2025.04.005. Epub 2025 Apr 18.
5
genotype and sex modulate Alzheimer's disease pathology in aged EFAD transgenic mice.
Front Aging Neurosci. 2023 Oct 31;15:1279343. doi: 10.3389/fnagi.2023.1279343. eCollection 2023.
6
Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood.
Alzheimers Dement (Amst). 2022 Nov 18;14(1):e12374. doi: 10.1002/dad2.12374. eCollection 2022.
8
Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.
Brain. 2022 Nov 21;145(11):4065-4079. doi: 10.1093/brain/awac213.
9
Age-Dependent Association Between Cognitive Reserve Proxy and Longitudinal White Matter Microstructure in Older Adults.
Front Psychol. 2022 Jun 10;13:859826. doi: 10.3389/fpsyg.2022.859826. eCollection 2022.
10
Rates of β-amyloid deposition indicate widespread simultaneous accumulation throughout the brain.
Neurobiol Aging. 2022 Jul;115:1-11. doi: 10.1016/j.neurobiolaging.2022.03.005. Epub 2022 Mar 14.

本文引用的文献

1
Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype.
Curr Alzheimer Res. 2014;11(8):773-84. doi: 10.2174/156720501108140910121920.
2
Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.
Neuropsychol Rev. 2014 Sep;24(3):290-9. doi: 10.1007/s11065-014-9263-8. Epub 2014 Aug 22.
3
CSF biomarker changes precede symptom onset of mild cognitive impairment.
Neurology. 2013 Nov 12;81(20):1753-8. doi: 10.1212/01.wnl.0000435558.98447.17. Epub 2013 Oct 16.
4
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8.
5
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.
Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83. doi: 10.1016/j.jalz.2012.10.007. Epub 2013 Jan 30.
6
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
Neurobiol Aging. 2013 Jan;34(1):1-12. doi: 10.1016/j.neurobiolaging.2012.04.017. Epub 2012 May 24.
8
Longitudinal patterns of β-amyloid deposition in nondemented older adults.
Arch Neurol. 2011 May;68(5):644-9. doi: 10.1001/archneurol.2011.77.
10
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.
Ann Neurol. 2011 Jan;69(1):181-92. doi: 10.1002/ana.22248.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验